pharmaphorum January 3, 2025
CARsgen Therapeutics’ claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid tumour.
The Shanghai-based biotech said the positive results from a phase 2 trial in advanced, claudin 18.2 expression-positive gastric or gastroesophageal junction (GEJ) cancers that have not responded to at least two prior lines of treatment could set up a regulatory filing for the CAR-T in China.
CAR-T therapies have transformed the treatment of various blood cancers, but have been less effective for solid tumours, in part because they find it difficult to target cancer cells, as well as infiltrate and survive in the hostile microenvironment of the tumour.
In the...
Today's Sponsors
Today's Sponsor